Randomised Evaluation of SOdium dialysate Levels on Vascular Events: A cluster Clinical Trial
Principal Investigators: A/Prof Meg Jardine
In the RESOLVE study, haemodialysis units Australia, New Zealand, China, India and other interested countries will be randomised for all patients to receive one of two sodium dialysate levels (137mmol/L or 140mmol/L). Incidents of major cardiovascular events are monitored (i.e. hospitalisation myocardial infarction, hospitalised stroke, coronary artery or cerebrovascular revascularisation and all-cause death) with trial data collected using existing regristries (i.e. ANZDATA in Australia and New Zealand). An application for New Zealand HRC project funding has been submitted and Australian NHMRC project funding will be applied for in 2016. International collaboration is led by the George Institute, Sydney and Australian collaboration is led by the Australasian Kidney Trials Network.